Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
154 Results for "
LAP
" in MedChemExpress (MCE) Product Catalog:
Products (154)
154 Results for "LAP" in MCE Product Catalog:
7
7 Cited Publications
Art. -Nr.: HY-44076
CAS. Nr.: 85073-19-4
Synonyms: Lithium phenyl-2,4,6-trimethylbenzoylphosphinate
81
81 Publications Verification
Art. -Nr.: HY-P7117
Reinheit: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFB1; Transforming Growth Factor Beta1; Prev. TGFB; Camurati-Engelmann Disease; Prev. DPD1; Latency-Associated Peptide; TGFbeta; TGF-Beta-1; CED; TGF-Beta1; Transforming Growth Factor Beta-1 Proprotein; IBDIMDE; Prepro-Transforming Growth Factor Beta-1; CAEND1; Transforming Growth Factor, Beta 1; LAP; Diaphyseal Dysplasia 1, Progressive; Transforming Growth Factor Beta 1; Transforming Growth Factor Beta
Species:
Rat
Mouse
Source:
HEK293
78
Target:
Forschungsgebiete:
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
78
Target:
Forschungsgebiete:
Cilengitide TFA (EMD 121974 TFA) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide TFA inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide TFA inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide TFA can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
61
61 Cited Publications
Art. -Nr.: HY-P70543
Reinheit: ≥ 95%, as determined by reducing SDS-PAGE or Bis-Tris PAGE.
Synonyms: TGFB1; Transforming Growth Factor Beta1; Prev. TGFB; Camurati-Engelmann Disease; Prev. DPD1; Latency-Associated Peptide; TGFbeta; TGF-Beta-1; CED; TGF-Beta1; Transforming Growth Factor Beta-1 Proprotein; IBDIMDE; Prepro-Transforming Growth Factor Beta-1;
Species:
Human
Source:
HEK293
18
18 Cited Publications
Art. -Nr.: HY-P0299
CAS. Nr.: 283609-79-0
Target:
Forschungsgebiete:
18
18 Cited Publications
Art. -Nr.: HY-P0299A
CAS. Nr.: 2828433-17-4
Target:
Forschungsgebiete:
7
7 Cited Publications
Art. -Nr.: HY-P78168
Reinheit: ≥ 90%, as determined by Bis-Tris PAGE.
Synonyms: TGFB1; Transforming Growth Factor Beta1; Prev. TGFB; Camurati-Engelmann Disease; Prev. DPD1; Latency-Associated Peptide; TGFbeta; TGF-Beta-1; CED; TGF-Beta1; Transforming Growth Factor Beta-1 Proprotein; IBDIMDE; Prepro-Transforming Growth Factor Beta-1; CAEND1; Transforming Growth Factor, Beta 1; LAP; Diaphyseal Dysplasia 1, Progressive; Transforming Growth Factor Beta 1; Transforming Growth Factor Beta
Species:
Human
Source:
HEK293
4
4
4 Cited Publications
Art. -Nr.: HY-P72238
Reinheit: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HSP90AA1; Heat Shock 86 KDa; Prev. HSPC1; FLJ31884; Prev. HSPCA; HSP90A; Prev. HSPCAL4; HSP 86; HSP90N; HSP86; Hsp89; LAP-2; Hsp90; Heat Shock Protein 90kDa Alpha Family Class A Member 1; Heat Shock Protein 90kDa Alpha (Cytosolic), Class A Member 1; Heat
Species:
Human
Source:
E. coli
3
3 Cited Publications
Art. -Nr.: HY-P78668
Reinheit: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFB1; Transforming Growth Factor Beta1; Prev. TGFB; Camurati-Engelmann Disease; Prev. DPD1; Latency-Associated Peptide; TGFbeta; TGF-Beta-1; CED; TGF-Beta1; Transforming Growth Factor Beta-1 Proprotein; IBDIMDE; Prepro-Transforming Growth Factor Beta-1; CAEND1; Transforming Growth Factor, Beta 1; LAP; Diaphyseal Dysplasia 1, Progressive; Transforming Growth Factor Beta 1; Transforming Growth Factor Beta
Species:
Human
Source:
HEK293
3
3 Cited Publications
Art. -Nr.: HY-P78213
Reinheit: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: TGFB1; Transforming Growth Factor Beta1; Prev. TGFB; Camurati-Engelmann Disease; Prev. DPD1; Latency-Associated Peptide; TGFbeta; TGF-Beta-1; CED; TGF-Beta1; Transforming Growth Factor Beta-1 Proprotein; IBDIMDE; Prepro-Transforming Growth Factor Beta-1; CAEND1; Transforming Growth Factor, Beta 1; LAP; Diaphyseal Dysplasia 1, Progressive; Transforming Growth Factor Beta 1; Transforming Growth Factor Beta
Species:
Human
Source:
HEK293
2
Target:
Forschungsgebiete:
L-AP4 (L-APB) is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively .
2
2 Cited Publications
Art. -Nr.: HY-P70433
Reinheit: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFB1; Transforming Growth Factor Beta1; Prev. TGFB; Camurati-Engelmann Disease; Prev. DPD1; Latency-Associated Peptide; TGFbeta; TGF-Beta-1; CED; TGF-Beta1; Transforming Growth Factor Beta-1 Proprotein; IBDIMDE; Prepro-Transforming Growth Factor Beta-1; CAEND1; Transforming Growth Factor, Beta 1; LAP; Diaphyseal Dysplasia 1, Progressive; Transforming Growth Factor Beta 1; Transforming Growth Factor Beta
Species:
Human
Source:
HEK293
2
2
2 Cited Publications
Art. -Nr.: HY-P72633
Reinheit: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GDF5; LAP-4; Growth Differentiation Factor 5; Cartilage-Derived Morphogenetic Protein 1; CDMP1; GDF5 Protein; BMP14; DUPANS; Growth/Differentiation Factor 5; CDMP-1; Bone Morphogenetic Protein 14; BDA1C; Cartilage-Derived Morphogenetic Protein-1; SYM1B; Lipopolysaccharide-Associated Protein 4; SYNS2; LPS-Associated Protein 4; GDF-5; Radotermin; LAP4; BMP-14; OS5
Species:
Human
Source:
E. coli
1
Application: cell culture, biological 3D printing, tissue engineering, etc.
1
1 Cited Publications
Art. -Nr.: HY-P70543G
Reinheit: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFB1; Transforming Growth Factor Beta1; Prev. TGFB; Camurati-Engelmann Disease; Prev. DPD1; Latency-Associated Peptide; TGFbeta; TGF-Beta-1; CED; TGF-Beta1; Transforming Growth Factor Beta-1 Proprotein; IBDIMDE; Prepro-Transforming Growth Factor Beta-1;
Species:
Human
Source:
CHO
1
1 Cited Publications
Art. -Nr.: HY-P73616
Reinheit: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFB1; Transforming Growth Factor Beta1; Prev. TGFB; Camurati-Engelmann Disease; Prev. DPD1; Latency-Associated Peptide; TGFbeta; TGF-Beta-1; CED; TGF-Beta1; Transforming Growth Factor Beta-1 Proprotein; IBDIMDE; Prepro-Transforming Growth Factor Beta-1; CAEND1; Transforming Growth Factor, Beta 1; LAP; Diaphyseal Dysplasia 1, Progressive; Transforming Growth Factor Beta 1; Transforming Growth Factor Beta
Species:
Human
Source:
HEK293
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
